The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
TCT 2021 | SIERRA trial updates: apamistamab in AML
Tania Jain, MBBS, Johns Hopkins University, Baltimore, MD, outlines key updates in the treatment of leukemia as presented at this year’s Transplantation & Cellular Therapy (TCT) 2021 meeting including two abstracts evaluating the use of targeted radioimmunotherapy with an anti-CD45 antibody, apamistamab (Iomab-B) in patients with acute myeloid leukemia. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
